AbbVie to present phase 3 etentamig data at myeloma meeting
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
More in Finance & Markets
Risk of Midterm ‘Blue Wave’ Leaves Defense Stocks Out of Favor
After two years of breakneck gains, shares of military contractors have hit a wall this year. Traders are expecting the pain to deepen further as they position for protracted negotiations and funding…
Bank ETF FTXO Delivered a 20% Return Over the Last Year. Here's Why I'd Choose IYF Instead.
FTXO targets banks with concentrated holdings and higher volatility, while IYF offers broader sector exposure at lower cost.
